---
title: "Nanobiotix S.A. (NBTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NBTX.US.md"
symbol: "NBTX.US"
name: "Nanobiotix S.A."
industry: "Biotechnology"
datetime: "2026-05-19T20:28:06.309Z"
locales:
  - [en](https://longbridge.com/en/quote/NBTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NBTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NBTX.US.md)
---

# Nanobiotix S.A. (NBTX.US)

## Company Overview

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.nanobiotix.com](https://www.nanobiotix.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.41)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 87 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 585.36% |  |
| Net Profit YoY | 62.34% |  |
| P/B Ratio | -24.18 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2399557933.76 |  |
| Revenue | 37554161.83 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 31.91% | A |
| Profit Margin | -73.52% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 585.36% | A |
| Net Profit YoY | 62.34% | B |
| Total Assets YoY | 13.49% | B |
| Net Assets YoY | -45.19% | E |
| Cash Flow Margin | 139.48% | B |
| OCF YoY | 585.36% | A |
| Turnover | 0.48 | C |
| Gearing Ratio | 224.68% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Nanobiotix S.A.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "585.36%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "62.34%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-24.18",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2399557933.76",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "37554161.83",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "31.91%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-73.52%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "585.36%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "62.34%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "13.49%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-45.19%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "139.48%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "585.36%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.48",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "224.68%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -86.91 | 544/386 | - | - | - |
| PB | -24.18 | 535/386 | - | - | - |
| PS (TTM) | 63.90 | 242/386 | 114.13 | 92.32 | 71.11 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 71% |
| Hold | 2 | 29% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 46.20 |
| Highest Target | 38.74 |
| Lowest Target | 25.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/NBTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/NBTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/NBTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/NBTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**